Gut hormones and diabetes mellitus

10.1042/bj0010028

10.3109/13813452909145169

Heller H, 1935, Über das insulinotrope Hormon der Darmschleimhaut (Duodenin), Naunyn‐Schmiedeberg's Arch Pharmacol, 147, 127

10.2337/diab.9.4.254

10.1210/jcem-24-10-1076

10.1210/jcem-25-10-1317

10.2337/diab.15.8.555

10.1007/BF01225454

10.1007/BF00281990

10.1002/dmr.5610030101

10.1016/B978-0-12-027311-9.50014-7

10.1210/jcem-63-2-492

Hampton SM, 1986, Insulin and C‐peptide levels after oral and intravenous glucose. Contribution of the enteroinsular axis to insulin secretion, Diabetes, 35, 612, 10.2337/diab.35.5.612

Tillil H, 1988, Dose‐dependent effects of oral and intravenous glucose on insulin secretion and clearance in normal humans, Am J Physiol, 254, E349

Shuster LT, 1988, Incretin effect due to increased secretion and decreased clearance of insulin in normal subjects, Diabetes, 37, 200, 10.2337/diab.37.2.200

Unger RH, 1969, Entero‐insular axis, Arch Mem Med, 123, 261

10.1007/BF00492251

10.1007/BF00499706

10.1016/0002-9610(75)90360-8

10.1210/edrv-9-1-122

10.1016/S0140-6736(87)91194-9

10.1111/j.1365-2362.1990.tb01896.x

10.1210/jcem-69-3-654

Nauck M, 1991, Insulinotropic effects of a combination of human synthetic GIP and GLP‐1 (7–36 amide) at physiological plasma glucose in man, Diabetologia, 34, A 14

Nauck MA, 1992, Preserved incretin activity of GLP‐1 (7–36 amide) but not of synthetic human GIP in patients with Type 2‐diabetes mellitus, Diabetologia, 35

10.1210/endo-103-2-610

10.1177/33.10.3900195

Ørskov C, 1987, Pancreatic and intestinal processing of proglucagon in man, Diabetologia, 30, 874, 10.1007/BF00274797

10.1016/0014-5793(88)81008-1

10.1177/25.12.925341

10.1159/000199846

10.1172/JCI111809

10.1210/jcem-65-3-395

10.1210/jcem-72-5-1123

Reimers J, 1988, Lack of insulinotropic effect of endogenous and exogenous cholecystokinin in man, Diabetologia, 14, 271, 10.1007/BF00277407

10.1172/JCI107315

Weaver MM, 1927, Distribution of pancreatic secretin in the gastrointestinal tract, Am J Physiol, 82, 106, 10.1152/ajplegacy.1927.82.1.106

10.1055/s-0028-1093649

10.1007/BF01219421

10.1210/jcem-50-3-603

10.1159/000197199

10.1172/JCI114055

10.1172/JCI114246

10.1210/endo-110-2-398

10.1210/endo-110-4-1268

10.1530/acta.0.1020096

Zawalich W, 1987, Interactions of cholecystokinin and glucose in rat pancreatic islets, Diabetes, 36, 426, 10.2337/diab.36.4.426

10.1210/endo-119-2-616

10.1007/BF00580278

Zawalich WS, 1987, Cholecystokinin‐induced alterations in β‐cell sensitivity. Duration, specificity, and involvement of phosphoinositide metabolism, Diabetes, 36, 1420, 10.2337/diab.36.12.1420

10.2337/diabetes.36.10.1212

Sandberg E, 1988, Cholecysrokinin‐33 potentiates and vasoactive intestinal polypeptide inhibits gastric inhibitory polypeptide‐induced insulin secretion in the perfused rat pancreas, Acta Endocrinol, 117, 545

10.1210/endo-94-4-1139

10.2337/diabetes.34.4.390

10.2337/diabetes.35.1.38

10.1016/0026-0495(88)90014-5

Zawalich WS, 1989, Interactions between cholinergic agonists and enteric factors in the regulation of insulin secretion from isolated perfused rat islets, Acta Endocrinol, 120, 702

10.1210/endo-114-5-1770

10.1111/j.1748-1716.1981.tb06730.x

10.1016/0016-5085(84)90524-9

Wang CC, 1951, Physiological determination of release of secretin and pancreozymin from intestine of dog with transplanted pancreas, Am J Physiol, 164, 527, 10.1152/ajplegacy.1951.164.2.527

10.1159/000176843

10.1210/jcem-70-5-1312

10.1016/0016-5085(91)90670-G

10.1111/j.1365-2362.1991.tb01402.x

BaumF NauckMA EbertR CantorP HoffmannG Roy ChoudhuryA SchmidtWE andCreutzfeldtW:The role of endogenously released cholecystokinin (CCK) in determining postprandial insulin levels in man: effects of loxiglumide a specific CCK receptor antagonist.Digestion(in press) 1993.

Niederau C, 1989, Effects of loxiglumide on gall bladder emptying in healthy volunteers, Gastroenterology, 97, 1331, 10.1016/0016-5085(89)91709-5

10.1016/S0140-6736(89)90255-9

10.1172/JCI114288

Schmidt WE, 1991, Role of CCK in regulation of pancreaticobiliary functions and GI motility in humans: effects of loxiglumide, Am J Physiol, 260, G197

10.1172/JCI114486

10.1172/JCI112401

10.1172/JCI113505

10.1111/j.1365-2362.1978.tb00800.x

10.1159/000199609

Enk B, 1976, Secretin‐induced insulin response. II. Dose‐response relation, Acta Endocrinol, 82, 312

Deckert T, 1968, Insulin secretion following administration of secretin in patients with diabetes mellitus, Acta Endocrinol, 59, 150

Hoist JJ, 1983, Gut glucagon, enteroglucagon, gut glucagon‐like immunoreactivity, glicentin‐current status, Gastroenterology, 84, 1602, 10.1016/0016-5085(83)90388-8

10.1007/BF00282517

10.1007/BF00251825

Hayakawa T, 1989, Enteroglucagon release in disaccharide malabsorption induced by intestinal alpha‐glucosidase inhibition, Am J Gastroenterol, 84, 523

10.1055/s-2007-999205

10.1210/endo-115-1-102

10.1056/NEJM198312153092406

Schusdziarra V, 1983, Somatostatin—physiological and pathophysiological aspects, Scand J Gastroenterol Suppl, 82, 69

10.2337/diabetes.39.10.1198

10.1007/BF00511208

10.1172/JCI113161

10.1210/endo-98-3-819

10.1210/endo-99-6-1452

10.1016/0024-3205(76)90400-8

10.1507/endocrj1954.28.631

10.1073/pnas.73.9.3197

10.1016/0024-3205(78)90246-1

10.1007/BF01228307

Holst JJ, 1987, VIP and PHI in the pig pancreas: coexistence, corelease, and cooperative effects, Am J Physiol, 252, G182

10.1152/ajpendo.1977.232.2.E197

10.1210/endo-112-4-1469

10.1038/284033a0

Rehfeld JF, 1971, Effect of gastrin and its C‐terminal tetrapeptide on insulin secretion in man, Acta Endocrinol, 66, 169

10.1016/0306-4522(83)90152-5

10.1016/S0016-5085(87)91071-7

10.1016/0167-0115(87)90284-9

Hoist JJ, 1983, GRP‐nerves in the control of pancreatic endocrine secretion, Diabetologia, 25, 165

10.1210/jcem-59-2-310

10.1177/27.9.479572

10.1210/endo-107-1-256

10.1152/ajpendo.1986.251.1.E127

10.1007/BF00313963

10.1152/ajpendo.1989.256.1.E191

10.1111/j.1748-1716.1990.tb08963.x

10.1530/acta.0.1190091

Su HC, 1987, Dual intrinsic and extrinsic origins of CGRP‐ and NPY‐immunoreactive nerves in rat gut and pancreas, J Neurosci, 7, 2674, 10.1523/JNEUROSCI.07-09-02674.1987

10.1210/endo-119-2-865

10.1016/0167-0115(88)90059-6

10.1210/endo-120-5-1774

10.1007/BF01239960

10.1152/physrev.1974.54.3.596

10.1210/edrv-2-4-471

10.1007/BF00870137

Holst JJ, 1983, Interrelation of nerves and hormones in stomach and pancreas, Scand J Gastroenterol Suppl, 82, 85

10.1016/0165-1838(86)90045-7

10.1073/pnas.88.24.11435

10.1016/0014-5793(91)80585-Q

10.2337/diabetes.38.9.1114

Åhren B, 1990, Effects of galanin and calcitonin gene‐related peptide on insulin and glucagon secretion in man, Acta Endocrinol, 123, 591

10.1056/NEJM198908243210806

10.2337/diab.39.5.634

10.2337/diacare.39.1.118

10.1038/276190a0

10.1210/endo-124-3-1254

10.1210/endo-119-2-685

10.1210/jcem-67-2-238

10.1016/0026-0495(87)90135-1

10.1172/JCI105685

10.1172/JCI112308

10.1210/jcem-63-2-401

Ebert R, 1980, Decreased GIP secretion through impairment of absorption, Front Horm Res, 7, 191

Qualmann C, 1992, Geringfügige insulinotrope Wirkung von exogenem und endogenem GLP‐1 [7–36 Amid] bei basalen Plasmaglucosekonzentrationen bei Stoffwechselgesunden, Diabetes Stoffw, 1, 134

10.1210/endo-128-6-3169

10.1016/0014-5793(87)81430-8

10.1210/endo-123-4-2009

10.1172/JCI112855

10.1016/0167-0115(88)90037-7

10.1210/endo-115-4-1324

10.2337/diabetes.36.11.1336

10.1677/joe.0.1160357

Göke R, 1989, Signal transmission after GLP‐1 (7–36) amide binding in RINm5F cells, Am J Physiol, 257, G397

10.1007/BF00291078

10.1210/jcem-56-2-234

Weir GC, 1989, Glucagonlike peptide 1 (7–37) actions on endocrine pancreas, Diabetes, 38, 338, 10.2337/diab.38.3.338

10.2337/diabetes.38.12.1534

10.1007/BF00456120

10.1210/jcem-70-5-1398

10.1210/endo-124-4-1768

Komatsu R, 1989, Glucagonostatic and insulinotropic action of glucagonlike peptide 1‐(7–36)‐amide, Diabetes, 38, 902, 10.2337/diab.38.7.902

10.2337/diabetes.28.12.1141

10.1172/JCI110335

10.1016/0167-0115(83)90131-3

10.1111/j.0954-6820.1984.tb03765.x

10.1007/BF01540341

10.1677/joe.0.1260169

NauckM BartelsE ØrskovC EbertR andCreutzfeldtW:Lack of effect of exogenous gastric inhibitory polypeptide (GIP) and glucagon‐like peptide 1 (GLP‐1) [7–36 amide] on pentagastrin‐stimulated gastric acid secretion in man.Digestion in press 1992.

10.1007/978-3-642-81771-7

10.1210/jcem-37-5-826

10.1152/ajpcell.1979.237.3.C185

Anderson DK, 1979, Oral glucose augmentation of insulin secretion. Interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels, J Clin Invest, 62, 152

10.1016/0014-5793(81)80288-8

10.1111/j.1432-1033.1984.tb08595.x

Moody AJ, 1984, The isolation and sequencing of human gastric inhibitory polypeptide (GIP) FEBS, Lett, 172, 142

10.1073/pnas.84.20.7005

Amland PF, 1984, Fasting and postprandial GIP values in pigs, rats, dogs, and man measured with five different GIP antisera, Scand J Gastroenterol, 19, 1095

10.3109/00365528509091657

10.1016/S0016-5085(74)80134-4

10.1177/000456327801500138

10.1677/joe.0.0850487

Ebert R, 1979, Release of gastric inhibitory polypeptide (GIP) by intraduodenal acidification in rats and humans and abolishment of the incretin effect of acid by GIP‐antiserum in rats, Gastroenterology, 76, 515, 10.1016/S0016-5085(79)80219-X

10.1210/jcem-39-2-223

10.1007/BF01221949

10.2337/diacare.5.4.379

10.1677/joe.0.0850201

10.1007/BF01072882

10.3109/00365528109182022

Ross SA, 1981, The importance of triglyceride hydrolysis for the release of gastric inhibitory polypeptide, Gastroenterology, 80, 108, 10.1016/0016-5085(81)90199-2

Tso P, 1981, Acute inhibition of intestinal lipid transport by pluronic L‐81 in the rat, Am J Physiol, 241, G487

10.1016/S0016-5085(76)80489-1

10.1016/0016-5085(78)90703-5

10.1152/ajpendo.1985.248.3.E299

10.1038/304368a0

10.1073/pnas.80.18.5485

Heinrich G, 1984, Glucagon gene sequence‐four of six exons encode separate functional domains of rat preproglucagon, J Biol Chem, 259, 14082, 10.1016/S0021-9258(18)89859-3

10.1007/BF00291980

10.1016/S0021-9258(18)51561-1

10.1016/S0021-9258(18)67324-7

10.1172/JCI115012

10.1007/BF00495439

10.1073/pnas.81.16.5007

10.3109/00365518709168885

10.1007/BF01296800

Gray GM, 1970, Carbohydrate digestion and absorption, Gastroenterology, 58, 96, 10.1016/S0016-5085(70)80098-1

10.1210/endo-128-6-3175

10.1113/jphysiol.1978.sp012477

10.1007/BF01212079

10.1007/BF01220640

10.1007/BF01851954

10.1111/j.1464-5491.1989.tb01285.x

Nauck M, 1990, Preserved incretin effect after heterotopic pancreas transplantation in type 1‐diabetic patients, Diabetologia, 33, A 38

10.1007/BF00422323

Louis‐Sylvestre J, 1976, Preabsorptive insulin release and hypoglycemia in rats, Am J Physiol, 230, 56, 10.1152/ajplegacy.1976.230.1.56

10.1016/0026-0495(78)90114-2

10.1152/ajpendo.1980.238.4.E336

10.1007/BF00254508

Strubbe JH, 1975, Rapid insulin release after ingestion of a meal in the unanesthetized rat, Am J Physiol, 229, 1919, 10.1152/ajplegacy.1975.229.4.1019

10.2337/diabetes.36.7.791

10.1152/ajpendo.1978.235.2.E103

10.1136/gut.21.11.1002

10.2337/diab.20.12.800

10.1016/0026-0495(87)90106-5

Niederkleine C, 1986, Incretin effect after oral and intragastric glucose: lack of oropharyngeal stimulation of insulin secretion in man, Diabetologia, 29, 575A

Chariot J, 1987, Cholinergic mechanisms in the pancreas after extrinsic denervation in the rat, Am J Physiol, 252, G755

10.1097/00006676-199101000-00001

10.1111/j.1365-2362.1992.tb01820.x

10.1007/BF00253866

10.2337/diabetes.33.4.389

Krarup T, 1985, Responses and molecular heterogeneity of IR‐GIP after intraduodenal glucose and fat, Am J Physiol, 249, E195

Krarup T, 1987, Effect of porcine 8000 dalton immunoreactive gastric inhibitory polypeptide in the isolated perfused pig pancreas, Diabetes, 36, 7A

Kreymann B, 1990, Haben GIP und GLP‐1 7–36 NH2 beim Menschen einen Inkretineffekt unter physiologischen Glucosekonzentrationen?, Akt Endokr Stoffw, 11, 130

10.1210/endo-111-5-1601

Ebert R, 1979, Release of gastric inhibitory polypeptide (GIP) by intraduodenal acidification in rats and humans and abolishment of the incretin effect of acid by GIP‐antiserum in rats, Gastroenterology, 76, 515, 10.1016/S0016-5085(79)80219-X

10.3109/00365528009181538

LauritsenKB ChristensenKC andStockholmKH:Gastric inhibitory polypeptide (GIP) release and incretin effect after oral glucose in obesity and after jejunoileal bypass. Scand JGastroenterol

10.1016/0014-5793(89)80899-3

10.1172/JCI105456

10.2337/diab.19.2.109

Yovos JG, 1982, Effects of amino acids and gastric inhibitory polypeptide on insulin release in dogs, Am J Physiol, 242, E53

10.2337/diacare.12.10.715

10.2337/diabetes.29.2.140

10.1007/BF01220638

10.1007/BF00422096

10.3109/00365528109181989

10.3109/00365528209182046

10.1007/BF00275269

10.2337/diab.37.6.667

10.1172/JCI111938

10.2337/diab.30.2.148

10.1002/dmr.5610020305

10.2337/diabetes.38.12.1501

Rahier JRD, 1989, Islet cell populations in obese subjects and type 2 (noninsulin‐dependent) diabetic patients, Diabetologia, 32, 532A

10.1056/NEJM198605223142106

10.1172/JCI105534

10.1056/NEJM198805123181903

10.1007/BF02427280

10.2337/diabetes.24.1.17

10.1530/acta.0.0550278

Lang DA, 1981, Brief irregular oscillations of plasma insulin and glucose concentrations in diabetic men, Diabetes, 30, 435, 10.2337/diab.30.5.435

Deacon CF, 1988, Preferential release of proinsulin relative to insulin in noninsulin‐dependent diabetes mellitus, Acta Endocrinol, 119, 549

10.2337/diabetes.38.11.1333

Tronier B, 1985, Absence of incretin effect in obese type II and diminished effect in lean type II and obese subjects, Diabetes Res Clin Pract, S568

Bloom SR, 1975, GIP in diabetes, Diabetologia, 11, 334

Ebert R, 1976, Serum gastric inhibitory polypeptide (GIP) response in patients with maturity onset diabetes and juvenile diabetes, Diabetologia, 12, 388

10.2337/diabetes.25.10.931

10.2337/diab.26.6.525

10.2337/diab.27.8.849

10.1210/jcem-51-2-254

10.1210/jcem-52-5-1002

10.1507/endocrj1954.28.17

10.1210/jcem-55-2-329

10.1210/jcem-58-6-1133

10.1210/jcem-61-2-313

10.1210/jcem-61-6-1089

10.1210/jcem-62-2-325

10.1007/BF00274255

Creutzfeldt W, 1983, Disturbances of the entero‐insular axis, Stand I Gastroenterol Suppl, 83, 111

10.1111/j.1365-2362.1979.tb01678.x

10.1007/BF00429703

Ross SA, 1974, Effects of gastric inhibitory polypeptide on endocrine pancreas in normal and diabetic subjects, Diabetologia, 10, 384

10.3109/00365528509091657

Jorde R, 1987, The insulinotropic effect of gastric inhibitory polypeptide in non‐insulin‐dependent diabetes, Ital J Gastroenterol, 19, 76

10.1055/s-2007-1009141

10.1016/0026-0495(87)90153-3

10.1007/BF00296993

10.2337/diabetes.39.11.1320

10.2337/diacare.15.2.270

10.1210/endo-128-6-2880

Schjoldager B, 1990, Truncated GLP‐1 (proglucagon 78–107–amide): a possible incretin from distal gut, Diabetologia, 33, A99

10.1210/jcem-69-3-571

Creutzfeldt W, 1983, Delaying Absorption as a Therapeutic Principle in Metabolic Disease

Gutniak M, 1990, Glucagon‐like insulinotropic peptide 1 (7–36)‐new approach to treating diabetes?, Diabetologia, 33, A73